CA2306692A1 - Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers - Google Patents

Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers Download PDF

Info

Publication number
CA2306692A1
CA2306692A1 CA002306692A CA2306692A CA2306692A1 CA 2306692 A1 CA2306692 A1 CA 2306692A1 CA 002306692 A CA002306692 A CA 002306692A CA 2306692 A CA2306692 A CA 2306692A CA 2306692 A1 CA2306692 A1 CA 2306692A1
Authority
CA
Canada
Prior art keywords
ch2f
asp
compound
cell death
ome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002306692A
Other languages
English (en)
Other versions
CA2306692C (fr
Inventor
John F. W. Keana
Sui Xiong Cai
John Guastella
Wu Yang
John A. Drewe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytovia Therapeutics LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2306692A1 publication Critical patent/CA2306692A1/fr
Application granted granted Critical
Publication of CA2306692C publication Critical patent/CA2306692C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/16—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

La présente invention concerne de nouveaux dipeptides représentés par la formule générale (I), dans laquelle R1-R3 et AA sont définis. Les composés correspondant à la formule (I) sont de puissants inhibiteurs de la mort cellulaire programmée. Par conséquent, les inhibiteurs décrits dans la présente invention peuvent retarder ou bloquer la mort cellulaire dans diverses conditions cliniques pouvant donner lieu à la perte de cellules, de tissus ou de la totalité des organes.
CA2306692A 1997-10-10 1998-10-09 Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers Expired - Fee Related CA2306692C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6167697P 1997-10-10 1997-10-10
US60/061,676 1997-10-10
PCT/US1998/021232 WO1999018781A1 (fr) 1997-10-10 1998-10-09 Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers

Publications (2)

Publication Number Publication Date
CA2306692A1 true CA2306692A1 (fr) 1999-04-22
CA2306692C CA2306692C (fr) 2010-09-21

Family

ID=22037372

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2306692A Expired - Fee Related CA2306692C (fr) 1997-10-10 1998-10-09 Dipeptides inhibiteurs de l'apoptose et utilisation de ces derniers

Country Status (10)

Country Link
EP (1) EP1033910A4 (fr)
JP (1) JP4439111B2 (fr)
KR (1) KR100580333B1 (fr)
CN (1) CN1138472C (fr)
AU (1) AU741203B2 (fr)
BR (1) BR9814817A (fr)
CA (1) CA2306692C (fr)
EA (1) EA200000409A1 (fr)
NO (1) NO20001323L (fr)
WO (1) WO1999018781A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
KR20010041905A (ko) * 1998-03-16 2001-05-25 시토비아 인크. 디펩티드 카스파제 억제제 및 이의 용도
DE69932434D1 (de) 1998-05-29 2006-08-31 Mochida Pharm Co Ltd Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE348163T1 (de) 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
EP1180991B1 (fr) 1999-02-01 2010-05-19 Cytovia, Inc. Acide de gomme-gute derives en tant qu'activateurs de caspases et inducteurs d'apoptose
EP1165490B1 (fr) 1999-03-16 2006-08-16 Cytovia, Inc. Inhibiteurs de caspases 2-aminobenzamidiques substitues et leur utilisation
CA2369619A1 (fr) * 1999-04-09 2000-10-19 Cytovia, Inc. Inhibiteurs de la caspase et leur utilisation
US6495522B1 (en) 1999-08-27 2002-12-17 Cytovia, Inc. Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
US6303374B1 (en) 2000-01-18 2001-10-16 Isis Pharmaceuticals Inc. Antisense modulation of caspase 3 expression
DE10006889A1 (de) * 2000-02-16 2001-09-06 Procorde Gmbh Verwendung von Inhibitoren von Caspase-3 oder der Caspase-aktivierten Desoxyribonuclease (CAD) zur Behandlung von Herzerkrankungen
US6689784B2 (en) * 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
SI1268425T1 (sl) 2000-03-29 2008-04-30 Vertex Pharma Zaviralci karbamat kaspaze in uporaba le-teh
NZ516918A (en) 2000-05-23 2004-06-25 Vertex Pharma Caspase inhibitors and uses thereof
US20020052323A1 (en) * 2000-08-30 2002-05-02 Jinhai Wang Quinoline-(C=O)-(multiple amino acids)-leaving group compounds for pharmaceutical compositions and reagents
JP2004509120A (ja) * 2000-09-13 2004-03-25 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼ阻害剤およびそれらの用途
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
MXPA03009647A (es) 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
MXPA05001367A (es) 2002-08-02 2005-04-28 Vertex Pharma Composiciones de pirazol utiles como inhibidores de gsk-3.
US20060212020A1 (en) * 2002-10-10 2006-09-21 Lynne Rainen Sample collection system with caspase inhibitor
CA2580796C (fr) 2004-09-24 2013-03-26 Amgen Inc. Molecules fc modifiees ayant des peptides inserees dans les regions de boucle interne
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP5249770B2 (ja) 2005-11-03 2013-07-31 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリジン
WO2008137619A2 (fr) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles et pyrazoles qui s'utilisent comme inhibiteurs de kinase
WO2009018415A1 (fr) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Procédé de préparation de la 5-fluoro-1h-pyrazolo[3,4-b]pyridin-3-amine et des dérivés de celle-ci
FR2923160B1 (fr) * 2007-11-02 2013-07-26 Pasteur Institut Composes destines a prevenir ou traiter une infection virale.
AU2009288200A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
CN106317161B (zh) * 2015-06-29 2020-05-15 深圳翰宇药业股份有限公司 一种氟甲基酮肽系列化合物的制备方法
CN117045634B (zh) * 2022-05-06 2025-10-10 北京康蒂尼药业股份有限公司 一种二肽衍生物组合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015577A1 (fr) * 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
DE69226820T2 (de) * 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
RU2206611C2 (ru) * 1991-08-30 2003-06-20 Вертекс Фармасьютикалз Инкорпорейтед ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−1β転換酵素阻害剤
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
ATE310528T1 (de) * 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie

Also Published As

Publication number Publication date
BR9814817A (pt) 2002-01-08
EA200000409A1 (ru) 2000-10-30
NO20001323D0 (no) 2000-03-14
EP1033910A1 (fr) 2000-09-13
AU9793098A (en) 1999-05-03
NO20001323L (no) 2000-06-13
CA2306692C (fr) 2010-09-21
CN1301131A (zh) 2001-06-27
AU741203B2 (en) 2001-11-22
KR100580333B1 (ko) 2006-05-16
CN1138472C (zh) 2004-02-18
WO1999018781A1 (fr) 1999-04-22
JP2001519358A (ja) 2001-10-23
EP1033910A4 (fr) 2004-11-24
JP4439111B2 (ja) 2010-03-24
KR20010031053A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
US6727227B1 (en) Tetrapetide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application
US6153591A (en) Dipeptide caspase inhibitors and the use thereof
JP5647995B2 (ja) 新規な抗老化ペプチド、並びにそれを含む化粧品及び/または製薬組成物
WO2021033830A1 (fr) Peptide ayant une activité favorisant la pousse des cheveux et son utilisation
JPS61212598A (ja) インシユリン化合物
KR20140026329A (ko) 사이클로스포린 유사체
CA2123516A1 (fr) Sels organiques de la n,n'-diacetylcystine
CN102272150B (zh) 新的抗衰老肽及含有所述肽的化妆品和/或药物组合物
KR20010031053A (ko) 디펩티드 고사 억제제 및 그의 용도
CN108699112A (zh) 呈现生发和/或育发促进活性的肽及其的用途
CZ287816B6 (en) Peptide, process of its preparation, pharmaceutical preparation in which it is comprised and use thereof
BR112014003051B1 (pt) Polipeptídeo, composição para estimular o crescimento de cabelo e uso dos mesmos
KR101713127B1 (ko) 저색소증 개선 및 지방 형성 억제 효능을 갖는 펩타이드 및 이의 용도
WO1990008130A1 (fr) Derives d'acide gras polyinsatures, compositions pharmaceutiques contenant ces derives, procede pour leur preparation et utilisation de ces derives comme medicament
WO2006059227A1 (fr) C-glycopeptides gem-difluores, leur preparation et leur utilisation pour la conservation de matieres biologiques et/ou la cryochirurgie
US20070099845A1 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US6831162B2 (en) Protein/polypeptide-k obtained from Momordica charantia and a process for the extraction thereof
DE69431603T2 (de) Oligopeptide hergeleitet von fragmenten des c-reaktiven proteins
FR2900656A1 (fr) Composes c-glycopeptides gem-difluores, leur preparation et leur utilisation notamment pour la preservation de materiaux biologiques
US5663148A (en) Anaphylatoxin receptor ligands containing lipophilic residues
US20060160748A1 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
EP0998494B1 (fr) Neuropeptides obtenus a partir de guepes pompiles
US9365633B2 (en) Peptide preparations and peptides with antitumour activity
RU94018525A (ru) Замещенные 2-гидрокси-3[1-(1н-имидазол-4-ил)алкил]-бензолкарбоксимидамиды, способы их получения и фармацевтическая композиция на их основе
JP3972104B2 (ja) 新規なヘクサペプチド及びアンジオテンシン変換酵素阻害剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141009